Metabolic profiles in diabetic subjects treated with human insulin (Novo) and porcine insulin.

Twenty-four-hour metabolic profiles were used to compare the efficacy of twice-daily injections of purified porcine and human Actrapid and Monotard insulins (Novo) in six insulin-treated diabetic subjects. Although both insulin regimens resulted in similar plasma glucose profiles, values were lower during the night with porcine insulin treatment. These differences in plasma glucose response may represent an increased effectiveness of porcine insulin. Alternatively, evaluation of the plasma glucose profiles by the mean of the daily differences suggests that inherent day-to-day variations in diabetic control could explain the differences observed. Also, the potency of the porcine insulin used was greater than that of the human insulin and may have contributed to the differences in glucose response. No differences were observed in pyruvate, lactate, total ketones, and insulin profiles over the 24-h period. No adverse reactions to human insulin occurred.

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

OBJECTIVE: To compare the effect of repaglinide in combination with metformin with monotherapy of each drug on glycemic control in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 83 patients with type 2 diabetes who had inadequate glycemic control (HbA1c > 7.1%) when receiving the antidiabetic agent metformin were enrolled in this multicenter, double-blind trial. Subjects were randomized to continue with their prestudy dose of metformin (n = 27), to continue with their prestudy dose of metformin with the addition of repaglinide (n = 27), or to receive repaglinide alone (n = 29). For patients receiving repaglinide, the optimal dose was determined during a 4- to 8-week titration and continued for a 3-month maintenance period. RESULTS: In subjects receiving combined therapy, HbA1c was reduced by 1.4 +/- 0.2%, from 8.3 to 6.9% (P = 0.0016) and fasting plasma glucose by 2.2 mmol/l (P = 0.0003). No significant changes were observed in subjects treated with either repaglinide or metformin monotherapy in HbA1c (0.4 and 0.3% decrease, respectively) or fasting plasma glucose (0.5 mmol/l increase and 0.3 mmol/l decrease respectively). Subjects receiving repaglinide either alone or in combination with metformin, had an increase in fasting levels of insulin between baseline and the end of the trial of 4.04 +/- 1.56 and 4.23 +/- 1.50 mU/l, respectively (P < 0.02). Gastrointestinal adverse events were common in the metformin group. An increase in body weight occurred in the repaglinide and combined therapy groups (2.4 +/- 0.5 and 3.0 +/- 0.5 kg, respectively; P < 0.05). CONCLUSIONS: Combined metformin and repaglinide therapy resulted in superior glycemic control compared with repaglinide or metformin monotherapy in patients with type 2 diabetes whose glycemia had not been well controlled on metformin alone. Repaglinide monotherapy was as effective as metformin monotherapy.

Intravenous immunoglobulin therapy for autoimmune diabetes mellitus.

OBJECTIVE: A variety of immune therapies have been used in an attempt to reduce the immune destruction of the insulin secreting beta cells which results in insulin dependent diabetes mellitus (IDDM). This study investigated the use of intravenous gammaglobulin therapy (IVIG) in children and adults with IDDM who participated in a two-year randomised controlled trial which also examined the effect of transfer factor in altering the natural course of IDDM. METHODS: Treatment was administered every two months for the duration of the study. IVIG was given in a dose of 2 g/ kg body weight in divided doses over two days. The other two groups received an intramuscular injection-the control group received normal saline and the transfer factor group received 1 i.u. of transfer factor. Remission rates, beta cell function and treatment side effects were assessed. RESULTS: Compared with the control group, IVIG therapy given every 2 months for 2 years, did not result in an increased number of complete remissions or differences in insulin dose, diabetes control or endogenous insulin secretion assessed as fasting and stimulated C-peptide responses to glucagon and a meal. IVIG therapy was associated with significant side effects. CONCLUSION: It is unlikely that IVIG therapy will be a viable option for immunotherapy in IDDM.

Polycystic ovary syndrome: a new direction in treatment.

Polycystic ovary syndrome is a diagnosis made in 5%-10% of women between late adolescence and the menopause. Patients may present with oligomenorrhoea or amenorrhoea, anovulation or infertility, hirsutism or acne. Women with the syndrome have at least seven times the risk of myocardial infarction and ischaemic heart disease of other women, and by the age of 40 years up to 40% will have type 2 diabetes or impaired glucose tolerance. Polycystic ovary syndrome is associated with insulin resistance, with consequent hyperinsulinaemia and (frequently) hyperlipidaemia and obesity. Recent research has shown that the application of diabetes management techniques aimed at reducing insulin resistance and hyperinsulinaemia (such as weight reduction and the administration of oral hypoglycaemic agents) can not only reverse testosterone and luteinising hormone abnormalities and infertility, but can also improve glucose, insulin and lipid profiles. The management of polycystic ovary syndrome should now include patient education and attention to diabetes and cardiovascular risk factors such as hyperlipidaemia, obesity, physical exercise, glucose intolerance, hypertension and cigarette smoking.

The emergency management of the diabetic at home.

The urgent admission to hospital of diabetic patients is often precipitated by hypoglycaemia, by vomiting or by ketoacidosis following cessation insulin therapy. By the use of simple agents, such as glucagon, lemonade and quick-acting insulin, such episodes can usually be averted in the early stages by the diabetic, his family and his doctor. These preventive measures keep the diabetic at work or at school and out of hospital, but require the provision of a simple emergency kit.

Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone.

Thirty sex offenders were randomly allocated: 10 to receive medroxyprogesterone therapy (M), 10, imaginal desensitization (ID) and 10 both (ID + M). Twenty-four responded for one year though 3 subsequently relapsed. There were no significant differences in response to the 3 treatments. Four patients who did not respond to the initial treatment and the 3 who relapsed responded to further treatment. Most treated with M maintained heterosexual intercourse at pretreatment frequency. Self-reported reduction in anomalous sexual urges in patients receiving M correlated with reduced testosterone levels one month following treatment, demonstrating that the response was specific and validating the assessment by patients' self-reports. Where cost-effectiveness or time constraints are factors influencing treatment of sex offenders, one of these therapies warrants consideration.

Resistance to treatment of adolescent sex offenders.

Little information is available concerning adolescent sexual offenders and their response to treatment. Of 45 sex offenders treated in two studies, 6 were adolescents and 21 of the 39 adults reported that their deviant behavior had commenced before or during adolescence. All 6 adolescents presented for treatment only following detection of their offenses, which in 3 led to legal charges. Of the 39 adults, 12 sought treatment voluntarily. Subjects were randomly allocated to receive covert sensitization, imaginal desensitization, medroxyprogesterone, or imaginal desensitization plus medroxyprogesterone. The response of the adults was equivalent to the best reported in the literature. Seven of the 39 required additional treatment, 3 being charged for further sexual offenses. Four of the 6 adolescents required additional treatment, 3 being charged with further sexual offenses. These differences were statistically significant. Adolescent sexual offenders may be more resistant to treatment because their sexual urges are under more direct hormonal control whereas in adults sexual urges are in part under the control of behavior completion mechanisms. Sexual offenses in adolescence need to be considered as at least as significant as those of adults, and more intensive follow-up treatment appears indicated in their management.

Treatment of severe diabetes mellitus by insulin infusion.

A new and simple form of insulin therapy for diabetic hyperglycaemia and ketoacidosis has been developed using a continuous intravenous infusion of insulin at a rate of 2.4 U/hr to maintain serum insulin concentration at physiological levels. This rate raises the mean serum insulin to 83 muU/ml and has a therapeutic effect which is not augmented by higher infusion rates. The response to such low doses of insulin indicates a need for a reappraisal of currently held theories about insulin resistance in diabetic ketoacidosis. In 11 diabetic patients with a mean plasma glucose of 514 mg/100 ml this therapy produced continuous falls in plasma glucose at a mean rate of 75 mg/100 ml/hr, and 10 out of 11 patients recovered within eight hours. This form of therapy is simple to institute, not complicated by hypoglycaemia, and avoids the confusion and empiricism of previously described forms of therapy.

Home blood glucose analysers. A consumer survey.

The seven home glucose analysers available on the Australian market were evaluated with respect to accuracy, ease of operation, price and additional features. At the same time, the BM-Test-Glycemie 20-800 dual sticks were assessed. The Boehringer Reflomat and Ames Eyetone can be regarded primarily as hospital instruments. The Ames Dextrometer, the Hypo-Count and both Stan Clark R.A.H.C. Glucose Testers were all adequate for home glucose monitoring. However, the Stan Clark R.A.H.C. Glucose Tester operating on Ames blood glucose reagent strips achieved the highest recommendation over all. The Glucochek was found to be an inconsistent instrument.

Cushing's disease presenting with avascular necrosis of the femoral heads and complicated by pituitary apoplexy.

A case of Cushing's disease presenting with avascular necrosis of the femoral heads is described. Eighteen months after the onset of hip symptoms the patient developed pituitary apoplexy and presented to hospital as a medical emergency. Endogenous hypercortisolism is a rare and important cause of avascular necrosis of bone.

Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group.

Polycystic ovary syndrome (PCOS) is classically characterised by ovarian dysfunction (oligomenorrhoea, anovulation and infertility), androgen excess (hirsutism and acne), obesity, and morphological abnormalities of the ovaries (cystic enlargement and stromal expansion). More recently, insulin resistance has been found to be common in PCOS, along with an increased prevalence of other features of the "metabolic syndrome", namely glucose intolerance, type 2 diabetes mellitus, and hyperlipidaemia. Hyperinsulinaemia is likely to contribute to the disordered ovarian function and androgen excess of PCOS. Reducing insulin resistance by lifestyle modifications such as diet and exercise improves endocrine and menstrual function in PCOS. These lifestyle modifications are the best initial means of improving insulin resistance. Metformin, an oral hypoglycaemic agent that increases insulin sensitivity, has been shown to reduce serum concentrations of insulin and androgens, to reduce hirsutism, and to improve ovulation rates. The effect of metformin alone on fertility rates is unknown. Some studies suggest that metformin will reduce total body weight to a small extent, but with a predominant effect on visceral adipose reduction. The effects of metformin on lipid abnormalities, hypertension or premature vascular disease are unknown, but the relative safety, moderate cost, and efficacy in reducing insulin resistance suggest that metformin may prove to be of benefit in combating these components of the "metabolic" syndrome in PCOS. Further properly planned randomised controlled trials are required.

Male pseudohermaphrodite reared as a female.

A 31-year-old male pseudohermaphrodite has been brought up as a female. The parents had told their child not to discuss the problem of ambiguous genitalia with anyone. As a teenager masculinization had occurred. Chromosome analysis of both peripheral blood and gonadal tissue was 46XY. The internal gonads were testes surrounded by a rim of ovarian stroma. A rudimentary cervix opened into a small vagina, as did the urethra in a valve-like fashion. The phallus was amputated during surgical reconstruction of the external genitalia to create a phenotypic female and the vagina was enlarged. Oestrogen therapy resulted in breast development.